Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The Prostate

• Publication date

  2010-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/pros.21093PMID 19938013PMCID PMC2925264
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.

  2008cited by this paper
• Laminin-332 Is a Substrate for Hepsin, a Protease Associated with Prostate Cancer Progression*

  2008cited by this paper
• Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

  2008cited by this paper
• Hepsin and prostate cancer.

  2007cited by this paper
• The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.

  2007cited by this paper
• Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.

  2007cited by this paper
• Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.

  2006cited by this paper
• Use of multiple biomarkers for a molecular diagnosis of prostate cancer

  2005cited by this paper
• Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.

  2005cited by this paper
• Small cell carcinoma of the urinary bladder

  2005cited by this paper
• Hepsin promotes prostate cancer progression and metastasis.

  2004influential reference
• Unusual subtypes of prostate cancer

  2004cited by this paper
• Revised classification of neuroendocrine tumours of the lung, pancreas and gut

  2004cited by this paper
• Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.

  2004cited by this paper
• Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee

  2004cited by this paper
• Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

  2003cited by this paper
• Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.

  2003cited by this paper
• Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

  2003cited by this paper
• Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue.

  2002cited by this paper
• Gene expression correlates of clinical prostate cancer behavior.

  2002cited by this paper
• Molecular Characterization of a Metastatic Neuroendocrine Cell Cancer Arising in the Prostates of Transgenic Mice* 210

  2002cited by this paper
• A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

  2001cited by this paper
• Delineation of prognostic biomarkers in prostate cancer

  2001cited by this paper
• Expression profiling reveals hepsin overexpression in prostate cancer.

  2001cited by this paper
• Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.

  2001cited by this paper
• Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.

  2001cited by this paper
• Small Cell Carcinoma of the Urinary Bladder

  2000cited by this paper
• Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.

  1999cited by this paper
• MYC oncogenes and human neoplastic disease

  1999cited by this paper
• Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization.

  1997cited by this paper
• Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.

  1997cited by this paper
• Prostate cancer progression, metastasis, and gene expression in transgenic mice.

  1997cited by this paper
• Emerging roles for proteinases in cancer.

  1997cited by this paper
• Prostate cancer in a transgenic mouse.

  1995cited by this paper
• Proteolytic remodeling of extracellular matrix.

  1995cited by this paper
• Prostatic carcinoma: histological and immunohistological factors affecting prognosis.

  1990cited by this paper
• Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia.

  1986cited by this paper
• Primary prostatic carcinoid tumor with intracytoplasmic prostatic acid phosphatase and prostate-specific antigen.

  1984cited by this paper
• Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. Immunohistochemical study and review of the literature

  1984cited by this paper
• Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland.

  1984cited by this paper
• Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland.

  1984cited by this paper
• The endocrine component of prostatic carcinomas, mixed adenocarcinoma‐carcinoid tumours and non‐tumour prostate. Histochemical and ultrastructural identification of the endocrine cells

  1981cited by this paper
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Small Composite Probasin Promoter Confers High Levels of Prostate-Specific Gene Expression through Regulation by Androgens and Glucocorticoids in Vitro and in Vivo*

  year unknowncited by this paper

• Diverse Landscape of Genetically Engineered Mouse Models: Genomic and Molecular Insights into Prostate Cancer.

  2024cites this paper
• Remodeling of the extracellular matrix by serine proteases as a prerequisite for cancer initiation and progression.

  2024cites this paper
• Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis

  2024cites this paper
• Pre-Clinical Models to Study Human Prostate Cancer

  2023cites this paper
• Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients

  2022cites this paper
• In Vivo Models for Prostate Cancer Research

  2022cites this paper
• Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer

  2022cites this paper
• Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers

  2020cites this paper
• Hepsin Promotes Epithelial–Mesenchymal Transition and Cell Invasion Through the miR-222/PPP2R2A/AKT Axis in Prostate Cancer

  2020cites this paper
• OTT_A_268025 12141..12149

  2020cites this paper
• Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model

  2019cites this paper
• Cell surface–anchored serine proteases in cancer progression and metastasis

  2019cites this paper
• Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

  2019cites this paper
• Telomerase Activity and Hepsin Gene Expression in Romanian Patients with Prostate Cancer: Preliminary Data

  2019cites this paper
• Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play

  2019cites this paper
• The Cell‐Surface, Transmembrane Serine Protease Hepsin: Discovery, Function and Role in Cancer

  2018cites this paper
• Expression of hepsin in prostate cancer and its biological implications

  2016cites this paper
• Type II transmembrane serine proteases as potential targets for cancer therapy

  2016cites this paper
• Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion

  2016cites this paper
• Drug discovery in prostate cancer mouse models

  2015cites this paper
• Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.

  2015cites this paper
• In vitro and in vivo model systems used in prostate cancer research.

  2015cites this paper
• Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice

  2015cites this paper
• Mouse models of prostate cancer: picking the best model for the question

  2014cites this paper
• HEV-ORF3 Encoding Phosphoprotein Interacts With Hepsin

  2014cites this paper
• Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.

  2014cites this paper
• Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic

  2013cites this paper
• Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity

  2012cites this paper
• Epithelial Integrity as a Tumor Suppressor Mechanism - The Interplay Between Lkb1 and c-Myc in Breast Cancer Development

  2012cites this paper
• Tumor suppressor function of Lkb 1 is linked to regulation of epithelial integrity

  2012cites this paper
• Weighted Change-Point Method for Detecting Differential Gene Expression in Breast Cancer Microarray Data

  2012cites this paper
• Faulty epithelial polarity genes and cancer.

  2011cites this paper
• Clinical and Biological Significance of Hepsin Overexpression in Breast Cancer

  2011cites this paper
• IGFBP-3 is a metastasis suppression gene in prostate cancer.

  2011cites this paper
• Proteolytic Processing of Laminin-332 by Hepsin and Matriptase and Its Role in Prostate Cancer Progression

  2011cites this paper
• Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells.

  2011cites this paper
• Mouse Models of Prostate Cancer

  2011cites this paper
• MYC and Prostate Cancer.

  2010cites this paper